Pharmaceuticals - Community Register


List of nationally authorised medicinal products for human use

Zinnat and associated names

Product name: Zinnat and associated names
Also marketed in the EU under the name(s): Cefuroxima Allen, Cefuroxima Solasma, Elobact, Nivador, Selan, Zinadol, Zipos, Zoref
Active substance: Cefuroxime (cefuroxime axetil)
Indication: Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months.
  • Acute streptococcal tonsillitis and pharyngitis.
  • Acute bacterial sinusitis.
  • Acute otitis media.
  • Acute exacerbations of chronic bronchitis.
  • Cystitis.
  • Pyelonephritis.
  • Uncomplicated skin and soft tissue infections.
  • Treatment of early Lyme disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Marketing Authorisation Holder: GlaxoSmithKline Research & Development Limited

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
27/08/2012 Referral EMEA/H/A-30/1157 (2012)6033 of 23/08/2012